With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the ...

Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

The Board of Directors continues to recommend stockholders vote “FOR” its three director nominees, Mary Ann Gray, Ph.D, Ran Nussbaum and Alpna Seth, Ph.D, at the upcoming 2025 Annual Meeting, which is ...

Keros Therapeutics shareholder ADAR1 Capital Management said it plans to withhold votes for board members Mary Ann Gray and Alpna Seth.

Asia-Pacific markets were set to mostly climb Friday, tracking Wall Street gains after U.S. President Donald Trump announced ...

Takeda reported an earnings per share (EPS) of -$0.23, missing the estimated EPS of -$0.03, indicating challenges in meeting ...

Explore Novavax's Q1 2025 earnings insights, highlighting raised revenue forecasts, strategic partnerships, and progress toward non-GAAP profitability ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...